Infection; Aspergillus
Conditions
Keywords
Aspergillus, Antifungal susceptibility, Azole resistance
Brief summary
Primary objectives: 1. To investigate the prevalence of azole resistance in Aspergillus clinical isolates collected in participating hospitals in Taiwan 2. To investigate the prevalence of azole resistance in Aspergillus environmental isolates in Taiwan 3. To characterize the molecular mechanisms of azole resistance in Aspergillus isolates in Taiwan 4. To investigate the clonality of Aspergillus clinical and environmental isolates in Taiwan 5. To describe the genetic relationships between local resistant strains with global strains Secondary objective: 1. To describe the clinical characteristics and treatment outcome of patients with proven or probable invasive aspergillosis 2. To evaluate the clinical impact of azole resistance in patients with proven or probable invasive aspergillosis in a case-control study
Detailed description
Cumulative evidence described the emergence and geographical expansion of azole-resistant Aspergillus fumigatus associated with azole treatment failure. Multiple amino acid substitutions in the cyp51A gene have been described to be associated with azole resistance that emerges during azole treatment, while a resistance mechanism, TR34/L98H mutation in cyp51A, has been linked to the agricultural use of azole fungicides in Europe, which have also been widely used in Taiwan for years. The current prevalence of azole-resistant Aspergillus isolates and mechanisms of azole resistance in Taiwan is not clear. Considering the potential of geographic migration of resistant isolates from neighboring countries and the possibility of emergence of locally revolved resistant strains, this 2-year multi-center project aims to investigate the prevalence rate of azole resistance in Aspergillus clinical and environmental isolates, to determine the molecular mechanisms of azole resistance, and to describe the clinical characteristics and treatment outcome of Aspergillus diseases in Taiwan. Clinical and environmental Aspergillus isolates will be collected and examined, and clinical data from patients with Aspergillus diseases or colonization will be retrieved and analyzed. Through this study the investigators anticipate increase in awareness of prevalence and impact of azole resistance in patient safety in participating hospitals. In addition, the investigators may update Taiwan treatment guideline for aspergillosis on the basis of these evidence and knowledge.
Interventions
None listed
Sponsors
National Health Research Institutes, Taiwan
National Taiwan University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
For primary objectives Inclusion Criteria: * Patients with one or more clinical specimens culture positive of Aspergillus
Exclusion criteria
* Is not a human pathogen of Aspergillus * no clinical data available For secondary objectives (a case-control study in a 1:4 ratio) Inclusion Criteria: * patients with proven or probable invasive aspergillosis Case patients: patients infected by azole-resistant isolates Control patients: patients infected by azole-susceptible isolates
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment success | 6 weeks after diagnosis of proven or probable invasive aspergillosis | The proportion of patients with complete response or partial response according to the definition described in Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. Sep 1 2008;47(5):674-683. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality | 6 weeks after diagnosis of proven or probable invasive aspergillosis | The proportion of non-survivors. Discharge against medical advice and in critical condition and lost to follow up will categorized as mortality. |
| Breakthrough mold infections | 6 weeks after diagnosis of proven or probable invasive aspergillosis | The proportion of patients with breakthrough mold infections |
| Breakthrough invasive fungal diseases | 12 weeks after diagnosis of proven or probable invasive aspergillosis | The proportion of patients with breakthrough invasive fungal diseases defined as occurrence of a proven or probable invasive fungal diseases according to EORTC/MSG revised definitions while on systemic antifungal therapy or within 15 days of discontinuation of antifungal use |
| Treatment success | 12 weeks after diagnosis of proven or probable invasive aspergillosis | The proportion of patients with complete response or partial response. |
Countries
Taiwan
Contacts
Primary ContactChen Yee-Chun, MD, PhD
Backup ContactICMJE
Outcome results
None listed